Darmstadt, Germany And New York (ots/PRNewswire) - Not intended for UK-based media - First of several registration trials expected to start in 2015 for the alliance between Merck and Pfizer - Initiation and first patient treated in Phase III clinical study recruiting across approximately 290 sites in more than 30 ...
Lyon, France (ots/PRNewswire) - European vaccine leader hosts events across the region to help raise awareness of immunization throughout life Sanofi Pasteur MSD welcomes the World Health Organization's European Immunization Week 2015 (EIW 2015) with a series of awareness-raising events across the region, taking place between April 20th and 25th. Sanofi Pasteur MSD, a European leader for vaccines in Europe, has joined ...
Geneva (ots/PRNewswire) - ASSESS shows plasma circulating tumour DNA (ctDNA) testing for EGFR mutation is a viable alternative to tumour biopsy IGNITE supports value of EGFR mutation testing in all patients with advanced NSCLC AstraZeneca today presented results from two key studies showing the effectiveness of plasma circulating tumour DNA (ctDNA) testing for ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm presents preclinical results for 2 anti-cancer targeted therapies Debio 1143 and Debio 1347 Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet ...
Tokyo (ots/PRNewswire) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that Swissmedic, the regulatory authority of Switzerland, has granted approval of Lixiana(R) (edoxaban), an oral, once-daily selective factor Xa inhibitor, for the prevention of stroke and systemic embolism (SE) in ...
Bagsværd, Denmark (ots/PRNewswire) - Today, Novo Nordisk announced a three-year extension of its Changing Diabetes(R) in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 ...
Edmonton, Alberta (ots/PRNewswire) - Stock Market Symbols GIB.A (TSX) GIB (NYSE) http://www.cgi.com/newsroom CGI is pleased to announce the renewal of its application maintenance services (AMS) contract with the Ministry of Health in Alberta (Alberta Health) for three years. The original contract was signed in 2011 for three and a half years, and the high quality work ...
Darmstadt, Germany And New York (ots/PRNewswire) - Not intended for UK-based media - In the second and third quarters of 2015, Merck and Pfizer will begin co-promoting XALKORI in the United States, Canada, Japan and five European Union countries (France, Germany, Italy, Spain and the United Kingdom) - In the United States and Canada, XALKORI will be co-promoted by EMD ...
Calgary, Alberta (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announces that it has received two China patent approvals covering RVX-208. A composition of matter patent, China No. 2007 8 0052349.8 titled, "Compounds for the Prevention and Treatment of Cardiovascular Disease" was granted until February 2027. A manufacturing patent, China No. ZL 2009 8 0106586.7 titled, "Methods of Preparing ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - - Potential Launch of SHP465 Anticipated in Second Half of 2017 - Exclusivity for Shire's Overall ADHD Product Portfolio Extends to 2029 Shire plc today announces that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on a clear regulatory path ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - Shire plc acknowledges the two petitions filed with the U.S. Patent and Trademark Office (USPTO) on April 2nd by Hayman Capital Management regarding LIALDA(R) (mesalamine) and GATTEX(R) (teduglutide [rDNA origin]). The patents listed in the FDA Orange Book for LIALDA and GATTEX protect the innovation and value Shire brings to patients who benefit from these important medicines. ...
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that the United Stated Patent and Trademark Office (USPTO) has ...
Takeda Pharmaceuticals Europe Ltd
Vienna (ots/PRNewswire) - FOR MEDICAL MEDIA Takeda Pharmaceuticals International GmbH ("Takeda") and Sunovion Pharmaceuticals Inc. ("Sunovion") today announced the results from three post-hoc analyses evaluating the efficacy and safety of Latuda(R) (lurasidone) in patients with schizophrenia at the 23rd European ...
Lausanne, Switzerland (ots/PRNewswire) - For non-US media - Global Rosacea Tweetathon set to bring the realities of living with rosacea under the spotlight #ChatRosacea Today the world's first Global Rosacea Coalition, supported by the National Rosacea Society and many leading rosacea experts, called for greater ...
Sunovion Pharmaceuticals Europe Ltd
Vienna (ots/PRNewswire) - Sunovion Pharmaceuticals Europe Ltd. will present 10 new research posters on LATUDA(R) (lurasidone), an atypical antipsychotic treatment for adults with schizophrenia, at the 23rd European Congress of Psychiatry (EPA). The meeting will be held 28-31 March 2015 in Vienna, Austria. "We are ...
Lyon, France (ots/PRNewswire) - European Committee for Medicinal Products for Human Use (CHMP) granted positive opinion for GARDASIL 9, the first 9-valent HPV vaccine Sanofi Pasteur MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted ...
Astellas Pharma Europe Limited
London (ots/PRNewswire) - Astellas Pharma Europe Ltd. today announced new data from the Phase 2 TERRAIN trial of enzalutamide compared to bicalutamide in metastatic castration-resistant prostate cancer (CRPC), as well as an updated overall survival analysis from the placebo-controlled Phase 3 PREVAIL trial of ...
Astellas Pharma Europe Ltd. and Medivation, Inc.
Chertsey, England (ots/PRNewswire) - Astellas Pharma Europe Ltd. and Medivation, Inc. announced that two enzalutamide abstracts will be presented at the annual European Association of Urology (EAU) Congress on March 24, 2015 in Madrid, Spain. (Logo: http://photos.prnewswire.com/prnh/20140522/689211 ) (Logo: ...
Cologne, Germany (ots/PRNewswire) - A prosthetic solution with the comfort of a fixed restoration; a patient-specific suprastructure on transgingival implants that eliminates the need for additional abutments; and an implant for sloped ridge situations for excellent esthetic results. (Logo: http://photos.prnewswire.com/prnh/20150310/732980-a ) (Logo: ...
Cologne, Germany (ots/PRNewswire) - DENTSPLY Implants remains strongly committed to innovation, science and clinical research. Parallel to expanding worldwide, DENTSPLY Implants has continued its dedication to innovation, science and clinical research. The company is now truly global and the commitment to the extensive clinical research program and innovative product ...
Lyon, France (ots/PRNewswire) - This decision opens the way to making Hexyon(R) available to more infantsin European countries Sanofi Pasteur MSD announced today that the European Commission has granted a new vaccination schedule of the 6-in-1 paediatric vaccine Hexyon(R) (DTaP-IPV-HB-Hib vaccine) for a "2+1" schedule of administration, in addition to other possible ...
Heidelberg (ots) - Roche and BioMed X announced today that they have entered into a collaboration agreement to establish a research group focusing on the development of a novel sensor technology platform based on new nanomaterials such as graphene. Outstanding early career scientists from leading academic ...
Parma And Modena, Italy (ots/PRNewswire) - The collaboration between a public excellent research center and a solid private pharmaceutical company allowed to achieve an extraordinary result, entirely "made in Italy": the first medicinal product containing stem cells approved in the Western world The European Commission has granted a conditional marketing authorization, ...
Darmstadt, Germany And Barcelona, Spain (ots/PRNewswire) - - Vall d'Hebron, Spain: first hospital to use liquid biopsy RAS biomarker testing technology - Leading research center will use technology to evolve understanding of who will benefit most from targeted treatment to improve patient outcomes - Liquid biopsy ...
Centre hospitalier Universitaire de Sherbrooke
Sherbrooke, Quebec (ots/PRNewswire) - - Download photos and videos at http://cr.chus.qc.ca/cyclotron-crchus #cyclotronCRCHUS Researchers at the Centre de research du Centre hospitalier universitaire de Sherbrooke (CRCHUS) unveiled today the results of a clinical study demonstrating equivalency between ...
Darmstadt, Germany (ots/PRNewswire) - In the news release, "Merck Strengthens Presence as Leading Oncology Company by Taking Full Promotional Responsibility for Erbitux in Japan" issued on 13 Feb 2015 06:33 GMT, by Merck over PR Newswire, we are advised by a representative of the company that in the third paragraph ...
Darmstadt, Germany (ots/PRNewswire) - - Not intended for US- and UK-based media - Merck and Bristol-Myers Squibb to end co-promotion of Erbitux in Japan, with full promotional responsibilities transferring to Merck Merck, a leading company for innovative and top-quality high-tech products in healthcare, life science ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - Shire plc announced today that the U.S. Food and Drug Administration (FDA) approved Vyvanse(R) (lisdexamfetamine dimesylate) Capsules (CII), the first and only medication for the treatment of moderate to severe binge eating disorder (B.E.D.) in adults, shown to ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts And Zug, Switzerland (ots/PRNewswire) - Shire plc announces that it has for the first time placed in the Global 100 Sustainability Index. Shire was ranked 62nd in the index, which is being revealed during the World Economic Forum in Davos this week. The Global 100 Index is a global ranking by Canada-based media and investment advisory company, Corporate Knights, of the top sustainability ...
Conakry, Guinea (ots/PRNewswire) - UC RUSAL , a leading global aluminium producer, announces that construction of the "Centre for epidemic and microbiological research and treatment" in the Kindia administrative region of the Republic of Guinea has completed. The Centre will support Guinea's national health system and help fight the spread of the Ebola virus. The opening ceremony which took place on 17 January was ...